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Abstract
For large-scale production, as required in structural biology, membrane proteins can be expressed in an insoluble form as inclusion bodies
and be refolded in vitro. This requires refolding conditions where the native form is thermodynamically stable and where nonproductive
pathways leading to aggregation are avoided. Examples of successful refolding are reviewed and general guidelines to establish refolding
protocols of membrane proteins are presented.
D 2003 Elsevier Science B.V. All rights reserved.
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1. Introduction
About one quarter of the human genes, amounting to
about 10,000, are predicted to encode for integral membrane
proteins (IMPs) [1]. Many of these reside in the plasma
membrane and mediate flow of information or substances
between the cytosol and extracellular space. Although often
expressed at low levels, IMPs perform key functions in
regulating the physiological state of the cell. This is espe-
cially true for receptors and ion channels that control second
messenger concentrations in the cytosol as well as the
transmembrane (TM) potential. These properties make them
especially suitable targets for pharmaceutical drugs, because
only low doses are required to achieve a desired effect. In
fact, more than two thirds of today’s drugs target these two
protein classes.
Of the thousands of proteins in the plasma membrane of
eukaryotic cells, only two are of known structure: rhodopsin
[2] and aquaporin [3]. Both proteins are naturally expressed
abundantly in the retina, respectively in erythrocytes. Rho-
dopsin is a special case, because it resides in intracellular
membrane stacks of rod outer segments, but these stacks are
probably derived from the plasma membrane [4]. All other
eukaryotic membrane proteins of known structure are from
intracellular membrane sources, that is, mitochondria, chlor-
oplasts and sarcoplasmic reticulum. The scarcity of IMP
structures is due to the well-known fact that the route from
membrane protein sequences to atomic-resolution structures
is not as straightforward as for their soluble counterparts.
One major obstacle is the production of multi-milligram
quantities of purified protein stable enough for crystalliza-
tion trials at relatively high concentrations [5]. Many differ-
ent expression systems have been considered and optimized
to achieve this goal, each with its own drawbacks. Typical
problems associated with heterologous expression of many
membrane proteins are low yield, often due to toxicity,
heterogeneous post-translational modification, low stability,
and partial proteolysis [5]. Most known membrane protein
structures result from proteins that naturally occur at high
concentrations or have been overexpressed in a homologous
system. However, the latter has been limited to bacterial
proteins. Heterologous expression in eukaryotic cells has
not yielded a single high-resolution membrane protein
structure to date (Table 1).
In view of this frustrating experience, it is worthwhile
to consider a radically different production method for
IMPs: expression in inclusion bodies followed by refolding
in vitro. In this procedure, targeting of the protein to
membranes is avoided. Instead, the expression system is
designed to result in the formation of cytoplasmic aggre-
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gates (inclusion bodies), yielding high levels of recombinant
protein. In a second step, the protein is solubilized and
folded in vitro into its native state. This obviously requires
that the protein can spontaneously fold into its (native)
energy-minimum.
The present review focuses on various aspects relevant to
in vitro folding of membrane proteins. Initially, the pros and
cons are summarized as to whether IMPs are thermodynami-
cally stable in micelles and therefore amenable to in vitro
folding at all. The subsequent section reviews examples of
successful overproduction of membrane proteins in inclu-
sion bodies. Finally, I will attempt to extract from the
published literature some general features of successful
refolding protocols.
Only IMPs of (presumed) alpha-helical structure will be
discussed here. Refolding of beta-barrel-type proteins resid-
ing in the outer membrane of bacteria, mitochondria and
chloroplasts has been achieved in several cases, eventually
leading to the growth of diffraction-quality crystals. The
methods used in this context are reminiscent of the well-
documented refolding protocols for soluble proteins and
have been reviewed elsewhere [6].
2. Stability of membrane proteins
The meaning of the word ‘‘stability’’ in everyday lan-
guage can be considerably different from its meaning in a
thermodynamic context. A protein that precipitates during
purification is not necessarily thermodynamically unstable.
On the other hand, a thermodynamically unstable protein
may remain folded for a long time under appropriate
conditions simply because denaturation has slow kinetics.
The following section highlights the implications of stabil-
ity/instability for in vitro refolding experiments with mem-
brane proteins.
2.1. Membrane proteins are unstable in micelles
Among protein biochemists, ‘‘membrane proteins are
often thought of as delicate weaklings, unable to withstand
the rigors of life outside the safety of the bilayer’’ [7]. This
summarizes the frustrating experience of numerous graduate
students who spent years on establishing a suitable purifi-
cation scheme for a membrane protein, whilst their lab
mates dealing with soluble proteins could proudly print a
3D structure onto the cover of their thesis. In fact, it is not
clear why membrane proteins solubilized in detergent often
suffer from activity loss and aggregation. No detergent can
provide an environment that perfectly mimics the lipid
bilayer. However, many soluble proteins in comparison
remain folded and active in solvents that strongly deviate
from the physiological situation, such as extreme pH, ionic
strength or replacement of half of the water by glycerol. The
relative instability of membrane proteins in detergent has
been attributed to (1) enhanced helix movements in the
micelle as compared to the bilayer, and (2) functional
requirement of IMPs for flexibility to achieve optimal
activity and turnover [7].
In line with these assumptions, the complete delipidation
of membrane proteins often results in a loss of activity.
Although specific interaction with lipids has been shown in
a number of cases [8–12], it is likely that some of these
interactions are promiscuous, that is, can be replaced by
other lipids as long as certain structural features are present.
For instance, G protein-coupled receptors (GPCRs) ex-
pressed in Escherichia coli have shown native pharmacol-
ogy [13–15], although E. coli lipids are predominantly
composed of phosphatidylethanolamine (PE), phosphatidyl-
glycerol (PG) and cardiolipin (CL), whereas the natural
bilayer environment of GPCRs is a mixture of mainly
phosphatidylcholine (PC), cholesterol, PE and phosphati-
dylserine (PS). Moreover, in contrast to eukaryotic mem-
branes, E. coli phospholipids lack polyunsaturated side
chains and contain cyclopropane groups not found in
mammalian phospholipids. This suggests that at least some
IMPs are rather forgiving concerning specific lipid inter-
actions. On the other hand, specific requirement for certain
lipids has been shown in a number of cases. For instance,
the oxytocin receptor and the nicotinic acetylcholine recep-
tor require cholesterol for high-affinity ligand binding and
stability [16]. Nevertheless, the physical properties of the
lipid bilayer such as bilayer thickness and lateral pressure
may be crucial for stability and have been shown to effect
the rate of refolding of bacteriorhodopsin (bR) [17] and
other membrane proteins. Mixtures of lipids and detergents,
so-called mixed micelles and bicelles [18], are probably
better solubilizing agents for inclusion bodies, because in
such a system, the lipids tend to cluster in the center of the
bicelle, close to the membrane protein and become arranged
in a bilayer-like fashion.
2.2. Membrane proteins are stable in micelles
The key question regarding in vitro folding of proteins is
whether the folded state corresponds to the global energy
minimum. The answer is not obvious for membrane pro-
teins, as the vectorial membrane insertion process in vivo
restricts the number of accessible conformations. As a
result, the native conformation may also be a kinetically
trapped local energy minimum. If this were the case, a
different folding pathway would be unlikely to yield the
native conformation.
Thermodynamic stability not only depends on the protein
and its surrounding detergent micelle, but also on the
environment. Therefore, the day-to-day experience of
‘‘instability’’, that is, loss of activity, does not necessarily
reflect an intrinsic property of the protein. It could simply
mean that the detergent, pH, etc. are ‘‘wrong’’ in the sense
that it allows for off-pathway reactions leading to kinetically
trapped states, such as aggregates. The following experi-
ments are in favor of membrane proteins being stable in
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detergent at least under certain conditions: First, some 30
different proteins have yielded 3D crystals starting from the
detergent-solubilized state. Crystals, however, can only
form if the majority of the molecules are in a defined
conformation, that is, during the days to weeks of crystal-
lization, no significant denaturation could have occurred.
Second, the following proteins have been refolded in vitro
from a denatured state, proving that the folding conditions
favor formation of native 3D structure: bR [19], light
harvesting complex [20], a number of mitochondrial carriers
[21,22], an olfactory receptor [23], and diacyl glycerol
kinase (DAGK) [24]. This is encouraging, because a suc-
cessful refolding experiment proves that loss of activity is
not necessarily a one-way street and that membrane proteins
may fold in vitro provided the proper folding conditions are
known.
Rosenbusch [25] recently speculated that exposure of
membrane proteins to detergent, in general, may have a
deteriorating effect and that the few proteins that could be
successfully crystallized are biased toward being exception-
ally stable. The recent addition of structures of presumably
‘‘difficult’’ proteins (ion channels, rhodopsin, abc trans-
porters) to the protein database questions this view. It is
also possible that some membrane proteins fail to crystallize
not because of poor stability, but because of extensive
conformational fluctuations that prevent formation of an
ordered array.
To summarize, practical problems in handling solubilized
IMPs do not necessarily reflect thermodynamic instability.
In several cases, stability of the native state in detergent
could be clearly established. Therefore, major progress in
IMP crystallization will result from the development of
improved methods that prevent unproductive reactions such
as aggregation. Whether these will simply involve synthesis
of novel detergents or more sophisticated methods such as
lipidic cubic phase crystallization, bicelle crystallization or
crystallization from organic solvents cannot be predicted
due to the low number of success cases obtained to date.
3. Practical aspects of refolding
3.1. How do IMPs fold in vivo?
How do membrane proteins adopt the native conforma-
tion in vivo and can we learn anything from these processes
for in vitro folding? In the cell, the protein is inserted co-
translationally into the membrane with the help of a protein
complex called the translocon. The translocon forms a
tunnel that allows translocation of regions destined for the
trans compartment as well as lateral release of hydrophobic
segments into the bilayer [26]. To date, this pathway is not
yet understood in enough detail to become exploited for
technical applications. However, direct insertion into mem-
branes with the help of translocase in combination with
lipidic cubic phase crystallization [25] might become an
option in the future to avoid the use of detergents altogether
in IMP crystallization.
What happens after membrane insertion? A widely held
concept explaining folding of IMPs is the two-stage model
of Popot and Engelman [27]. This model postulates that in a
first stage, individual TM stretches form stable alpha helices
in the membrane once they become inserted. Only in the
second stage do they associate to form tertiary contacts at
the helix interfaces, resulting in formation of the native 3D
structure [27].
The notion that individual TM stretches are domains that
fold in a membrane environment has been partly questioned
by a study on bR. Hunt et al. [28] synthesized peptides
corresponding to the seven TM domains and investigated
their structure in a lipid bilayer. Four of the seven peptides
formed stable alpha helices, while the others showed various
degrees of secondary structure and membrane partitioning,
implying that tertiary contacts seem to be necessary for
these latter regions in the protein to acquire a stable fold.
The two-stage model may serve as a guideline for in vitro
folding. It is likely that even under artificial conditions such
as a detergent micelle, alpha-helix formation will precede
the formation of tertiary contacts. Therefore, conditions that
promote the formation of alpha helix, as monitored by, for
example, CD spectroscopy, might be a good starting point
for further experiments aimed at obtaining the folded con-
formation.
3.2. Source of denatured protein
E. coli is by far the most important host of proteins
produced for crystallization. Of the 31 IMPs listed in Table
1, 10 were produced in this bacterium. Notably, the only
four membrane proteins expressed in a nonhomologous host
and yielding an X-ray structure were produced in E. coli.
Table 1
Number of alpha-helical IMPs yielding high-resolution X-ray structures
[40] grouped by expression host and source of gene
Source of gene Expression host
E. coli Other bacteria
and archaea
Mitochondria Other
eukaryotic
membranes
E. coli 6a – – –
Other bacteria
and archaea
4b 14c – –
Mitochondria – – 4d –
Other eukaryotic
membranes
– – – 3e
The above list contains pdb entries. If several entries exist for the same
protein, only one is listed. Only the four structures listed under b are derived
from a recombinant source (E. coli); all others are from natural sources.
a 1FFT, 1FUM, 1FX8, 1KPL, 1KQF, 1L7V.
b 1H68, 1BL8, 1MSL, 1KPK.
c 1PRC, 4RCR, 1EYS, 1JBO, 1BRX, 1E12, 1H68, 1KZU, 1LGH,
1IJD, 1QLE, 1AR1, 1EHK, 1E7P.
d 1OCR, 1QRC, 1BCC, 1KB9.
e 1F88, 1J4N, 1EUL.
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The reasons for its popularity include the vast choice of
expression vectors, rapid cell growth, standardized scaling-
up procedures as well as low cost per milligram of protein.
Auxotrophic strains enabling selenomethionine labeling are
of additional value in obtaining phase information of dif-
fraction data.
Because many attempts to functionally overexpress
eukaryotic membrane proteins in bacteria resulted in tox-
icity and consequently low yields, alternative strategies have
been envisaged. A promising improvement of this situation
was the selection of E. coli mutants that could tolerate
expression of normally toxic membrane proteins [29,30].
The selected strains markedly increased expression levels of
some proteins. However, for other proteins, no improvement
could be obtained. When successful, induction of protein
production led to the formation of membrane stacks and the
increase in expression levels correlated with an increase in
membrane surface area.
Alternatively, the toxicity could be abolished when the
membrane protein was not inserted into the membrane but
instead deposited in the cytoplasm in an aggregated state
denoted ‘‘inclusion bodies’’. For some proteins, for exam-
ple, mitochondrial transporters [22], cytoplasmic aggrega-
tion happens spontaneously. Others, such as GPCRs, can be
preferentially directed to the cytoplasm by including an N-
terminal fusion and/or by introducing positively charged
amino acids into the loop regions to prevent translocation
[23,31]. In any case, inclusion body formation correlates
with a dramatic increase in expression levels, often by a
factor of 1000 to 10,000 as compared to functional expres-
sion in the membrane.
Inclusion body formation is thought to depend on the
kinetic competition between protein folding (in the case of
membrane proteins, by membrane insertion) and the aggre-
gation of unfolded protein. Therefore, inclusion bodies can
be promoted (1) by slowing down the folding and mem-
brane insertion kinetics, for example, by reducing the
growth temperature (unpublished observations); and (2) by
increasing the protein concentration, because aggregation is
a higher order reaction. An N-terminal fusion can help in
several ways. First, if the N-terminal domain alone is
expressed at high levels, it is likely to improve expression
of the C-terminal fusion partner. Second, slow folding of the
fusion protein will promote aggregation. Third, if the N
terminus of the native membrane protein is extracellular, the
fusion will preclude translocation and reduce the fraction of
membrane-inserted protein. For the expression of GPCRs,
an N-terminal glutathione S-transferase (GST) fusion has
been proven to increase protein production by a factor of
1000 to 10,000. Other soluble proteins fused to the N
terminus (lacZ, malE, ZZ domain of protein A, thioredoxin)
were much less efficient (our unpublished data). These
proteins tend to confer better solubility to their C-terminal
fusion partners, which, in the present case, is not desired.
Even eukaryotic organisms such as yeast [32] or insect
cells [33] have been shown to yield inclusion body protein
in some cases. However, it is not known whether proteins
can be driven to form aggregates in those systems. An
obvious advantage would be that codon usage problems
resulting from transfer of mammalian genes to the host are
less likely to occur in eukaryotic cells than in bacteria.
However, I am not aware of any literature exploiting this
possibility.
Finally, cell-free synthesis of membrane proteins leading
to aggregation could possibly yield higher quantities than
the attempt to express directly into detergent micelles or
membranes, because the added detergents might interfere
with the transcription/translation system. However, in cell-
free protein synthesis, like in eukaryotic expression systems,
aggregation is generally considered a nuisance and avoided
whenever possible.
A successful system yielding high protein levels has been
described by Smith and Johnson [34]. It has been used by us
to overproduce some 50 different GPCRs with yields rang-
ing from 0.5 to 50 mg/l cell culture, with 5–10 mg being the
typical yield [31].
3.3. Analysis of published refolding protocols
For practical applications, the necessary requirement is
that conditions are found that thermodynamically favor the
native conformation over the denatured state. Moreover,
pathways leading to the formation of trapped, nonproductive
states such as aggregates have to be avoided. The folding
pathway, however, can be very different from the in vivo
situation.
It is instructive to compare the protocols describing
successful renaturation of membrane proteins from E. coli
inclusion bodies (references cited in Section 2.2). Although
the procedures differ in detail, the following steps are
common to all of them: (1) Solubilization in either a strong
detergent, a chaotrope or in organic solvent; (2) transfer into
a strong detergent, if not already achieved in (1); (3)
addition of mixed phospholipid detergent micelles; and (4)
removal of detergent. Folding as assessed by functional
measurements, occurred either at step 3 or 4. In the follow-
ing, the individual steps are analyzed in more detail.
3.3.1. Solubilization
The relatively small proteins light harvesting complex
(LHCP) [20] and DAGK [24] were soluble in the chaotrope
urea and could be coupled to a Ni-column in the urea-
solubilized state. Mitochondrial transporters [35] as well as
the rat olfactory receptor OR5 [23] were solubilized in the
strong, negatively charged, detergent N-lauroyl sarcosine.
Even for DAGK, solubilisation in the detergent dodecylphos-
phocholine (DPC) was eventually considered more success-
ful than urea solubilisation. bR [19], finally, was extracted
and completely denatured, in organic solvent, that is, a
mixture of chloroform, methanol, water and trimethylamine.
Alkyl ionic detergents such as SDS and sarkosyl are
considered ‘‘strong’’ or ‘‘harsh’’ due to their denaturing
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effect on most proteins [36]. DPC is a zwitterionic detergent
and therefore possibly less disruptive. Literature describing
its use in solubilizing native membrane proteins is scarce,
though, indicating that DPC should be classified as a harsh
detergent as well.
3.3.2. Transfer into harsh detergent
Proteins solubilized in urea or organic solvent were
transferred into a strong detergent. This was achieved either
by simple solvent exchange of the matrix-bound protein
(LHCP), or by adding SDS to bR dissolved in organic
solvent, removing the solvent in vacuo, and finally resus-
pending the protein in aqueous buffer.
3.3.3. Addition of mixed lipid/detergent micelles
In the case of LHCP, this was preceded by exchanging
the detergent SDS for OG. Then, mixed micelles of Triton
X-100 and dipalmitoyl phophatidylglycerol (DPPG) were
added. For OR5, sarkosyl was first replaced by digitonin.
Subsequently, mixed micelles of dodecyl maltoside and 1-
palmitoyl-2-oleoyl PC (POPC) and 1-palmitoyl-2-oleoyl PG
(POPG) were added. To bR, the mixed micelles consisted of
CHAPS and DMPC, whereas for DAGK, a mixture of DPC
and POPC proved to be most successful. Finally, mitochon-
drial transporters were transferred into a mixture of Triton
X-100 and phospholipids. In all cases, the molar ratio of
detergent to lipid was between 5 and 10, while the mass
ratio of detergent to protein was 5 or higher, corresponding
to a minimum molar ratio of 500 detergent molecules plus
50 phospholipid molecules per protein. In three cases, it
could be established by functional measurement that the
protein refolded into the native state in the detergent/lipid
mixture, namely, for bR, LHCP and OR5. Interestingly, bR
did not require removal of SDS to become functional;
instead, a ca. 8-fold excess of the CHAPS/DMPC mixture
induced refolding. The remaining proteins (mitochondrial
transporters and DAGK) required complete removal of
detergent (sarkosyl/DPC) before any function could be
detected.
3.3.4. Removal of detergent
This procedure was carried out either by dialysis
(DAGK/DPC, bR) or by treatment with a hydrophobic
matrix adsorbing the detergent (mitochondrial carriers:
Amberlite; DAGK: Biobeads; OR5: Calbiosorb). LHCP
was not reconstituted into liposomes.
3.4. A rational approach toward membrane protein
folding?
What is the rational basis of these refolding protocols? To
understand each process in some detail and to be able to
design rational screens allowing to find and optimize
refolding conditions for new proteins, the following ques-
tions would require an answer: (1) What is the structure of
membrane protein in inclusion bodies? (2) Why is the
‘‘harsh’’ detergent required? (3) What is the conformation
of the protein in the harsh detergent? (4) What happens upon
folding?
The answer to question (1) is still pending. Proteins in
inclusion bodies are not easily amenable to biophysical
investigation, especially not if other contaminating proteins
are present as is often the case. For inclusion bodies formed
from soluble proteins, considerable secondary structure has
been detected by CD spectroscopy, but similar experiments
have not been published for membrane protein inclusion
bodies. It is clear though that IMPs can aggregate in differ-
ent ways leading to aggregates that do become soluble in
strong detergents, such as IBs, and ‘‘irreversible’’ aggre-
gates that do not, such as precipitates obtained, for example,
from heating solubilized IMPs (unpublished observation).
As long as the structure of protein in inclusion bodies is
unknown, better solubilization methods will be a result of
trial and error even in the future.
Concerning the second question, the most likely answer
is that harsh detergents are required to prevent proteins from
aggregating before folding is induced. The negative surface
charge on SDS or sarkosyl micelles will electrostatically
prevent close contact between protein molecules. At the
same time, these detergents induce alpha-helix formation
upon binding to the hydrophobic TM segments. Therefore,
in a mixed protein/SDS (or sarkosyl) micelle, the protein
will probably have considerable secondary structure and be
in a good starting position for subsequent formation of
tertiary contacts. In a later folding step, these detergents
will no longer be required and have to be replaced by milder
detergents, respectively a lipid bilayer. The situation is
reminiscent of the use of detergents as ‘‘artificial chaper-
ones’’ to refold soluble proteins [37]. Here, detergents are
needed temporarily to prevent aggregation. The folded
protein no longer requires any detergent as stabilizer.
The third question relates to the conformation of IMPs
solubilized in harsh detergents. When analyzed, alpha-
helical structure could be detected and mostly corresponded
to the expected fraction of alpha helix in the folded protein.
Still, the function of proteins in SDS or sarkosyl is impaired:
the visible spectrum of bR indicates that the chromophore is
exposed to solvents, DAGK does not trimerize and therefore
has no enzymatic activity, lactose permease (LacY) loses its
ability to bind substrate and so do many GPCRs. It seems
therefore that these proteins in SDS or sarkosyl are in a
molten globule-like state that contains considerable secon-
dary structure but not the native tertiary fold. This view is
supported by a number of IMPs running abnormally, that is,
with a lower than expected molecular mass, on SDS-PAGE,
indicating that they are more compact than their soluble,
completely unfolded, counterparts. This, in combination
with the fact that multimeric proteins are dissociated in
SDS, favors the assumption that SDS-solubilized IMPs are
molten globules.
Finally, what happens upon folding? The denaturing
detergent is removed and replaced either directly by lipid
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or by a milder detergent, respectively by detergent/lipid
mixtures. In either case, functional measurements were used
to quantify the folded state. The portion of the protein that
becomes functional must have formed proper helix–helix
contacts upon transfer into the more bilayer-like environ-
ment. bR is the only IMP where refolding kinetics has been
studied thoroughly [38], indicating that helix–helix assem-
bly precedes binding of the chromophore retinal. With the
exception of bR, 100% refolding yield could never be
achieved, though.
In lack of a detailed theoretical understanding of the
various factors affecting refolding yields and tendency to
aggregate, the most straightforward strategy to find suitable
folding conditions is to vary all the parameters, especially
the composition of detergent/lipid micelles, in a systematic
way and quantify the refolding yield. A proper functional
assay that works in detergent is therefore a crucial success
factor. Obviously, this is easier to achieve for IMPs with
ligand binding properties than for proteins that require
membrane reconstitution to become active such as, for
example, voltage-gated ion channels.
Future progress in membrane protein refolding could
come from automation, allowing screening of many more
folding conditions than can be routinely achieved to date.
Also, physical methods that distinguish between folded and
nonfolded conformation, such as CD or light scattering,
could contribute to an increase in throughput and speed.
Finally, methods that stabilize membrane proteins such as
random mutagenesis and selection of more stable mutants
[39] might help to make even the weakest weaklings ame-
nable to crystallization and, eventually, structural analysis.
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